The production of peptides as active pharmaceutical ingredients (APIs) by recombinant technologies is of emerging interest. A reliable production platform, however, is still missing due to the inherent characteristics of peptides such as proteolytic sensitivity, aggregation, and cytotoxicity.
Numaswitch, a new technology solving present limitations. Numaswitch was successfully employed for the production of diverse peptides and small proteins varying in length,
physicochemical and functional characteristics, including Teriparatide, Linaclotide, human β- amyloid and Serum amyloid A3.
Additionally, the potential of Numaswitch for a cost-efficient commercial production is demonstrated yielding > 2 g Teriparatide per liter fermentation broth in a quality meeting API standard.
Numaswitch – an efficient high-titer expression platform to produce peptides and small proteins
Bach‑Ngan Nguyen, Florian Tieves, Thomas Rohr, Hilke Wobst, Felix S. Schöpf, Jóse D. Montoya Solano, Julia Schneider, Janpeter Stock, Andreas Uhde, Thomas Kalthof, Karl Erich Jaeger, Lutz Schmitt and Christian Schwarz
AMB Expr (2021) 11:48